Endotoxin in the pathogenesis of sepsis

Contributions to Nephrology

Volumn 167, Issue , 2010, Pages 1-13

  Marshall, John C ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN;

BACTERIAL INFECTION; ENDOTOXEMIA; HISTORY; HUMAN; INFANT; INFECTION; INTENSIVE CARE UNIT; MICROBIOLOGY; MORTALITY; PUBLIC HEALTH; REVIEW; SEPSIS; STANDARD; STATISTICS;

BACTERIAL INFECTIONS; ENDOTOXEMIA; ENDOTOXINS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; INFANT; INFECTION; INTENSIVE CARE UNITS; MICROBIOLOGY; PUBLIC HEALTH; SEPSIS;

EID: 77954591684     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315914     Document Type: Article

References (49)

1. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
3. Majno G: The ancient riddle of sigma psi iota sigma (sepsis). J Inf Dis 1991;163:937-945.
4. Capps JA, Coleman GH: Influence of alcohol on prognosis of pneumonia in Cook County Hospital. JAMA 1923;80:750-752.
5. Rogers DE: The changing pattern of lifethreatening microbial disease. N Engl J Med 1959;261:677-683.
6. Achievements in public health, 1900-1999. MMWR 1999;48:621-629.
7. Atkins E, Wood WB Jr: Studies on the pathogenesis of fever. II. Identification of an endogenous pyrogen in the blood stream following the injection of typhoid vaccine. J Exp Med 1955;102:499-516.
8. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE: The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980;141:55-63.
9. Wiles JB, Cerra FB, Siegel JH, Border JR: The systemic septic response: does the organism matter̈ Crit Care Med 1980;8:55-60.
10. Deutschman CS, Konstantinides FN, Tsai M, Simmons RL, Cerra FB: Physiology and metabolism in isolated viral septicemia. Further evidence of an organism independent host dependent response. Arch Surg 1987;122:21-25.
11. Watters JM, Bessey PQ, Dinarello CA, Wolff SM, Wilmore DW: Both inflammatory and endocrine mediators stimulate host responses to sepsis. Arch Surg 1986;121:179-190.
12. Michie HR, Spriggs DR, Manogue KR, et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988;104:280-286.
13. Marshall JC, Sweeney D: Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 1990;125:17-23.
14. Marshall JC: Rethinking sepsis: from concepts to syndromes to diseases. Sepsis 1999; 3:5-10.
15. Guarner F, Malagelada JR: Gut flora in health and disease. Lancet 2003;361:512-519.
16. Savage DC: Microbial ecology of the gastrointestinal tract. Annu Rev Med 1977;31:107-133.
17. Gill SR, Pop M, Deboy RT, et al: Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-1359.
18. Matzinger P: The danger model: a renewed sense of self. Science 2002;296:301-305.
19. Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Tolllike receptors. Semin Immunol 2007;19:3-10.
20. Imai Y, Kuba K, Neely GG, et al: Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008;133:235-249.
21. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'neill SJ, McElvaney NG: Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett 2003; 544:129-132.
22. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al: The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-1143.
23. Marshall JC: Lipopolysaccharide: an endotoxin or an exogenous hormone? Clin Infect Dis 2005;41(Suppl 7):S470-S480.
24. Calvano SE, Xiao W, Richards DR, et al: A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-1037.
25. Dyall SD, Brown MT, Johnson PJ: Ancient invasions: from endosymbionts to organelles. Science 2004;304:253-257.
26. Zhang Q, Raoof M, Chen Y, et al: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-107.
27. Opal SM, Scannon PJ, Vincent JL, et al: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-1589.
28. Marshall JC, Foster D, Vincent JL, et al: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004;190:527-534.
29. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE: Endotoxemia in human septic shock. Chest 1991;99:169-175.
30. Bates DW, Parsonnet J, Ketchum PA, et al: Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group. Clin Infect Dis 1998;27:582-591.
31. Riddington DW, Venkatesh B, Boivin CM, et al: Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996;275:1007-1012.
32. Niebauer J, Volk HD, Kemp M, et al: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842.
33. Goncalves S, Pecoits-Filho R, Perreto S, et al: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006;21:2788-2794.
34. Lin CY, Tsai IF, Ho YP, et al: Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007;46: 816-826.
35. Roumen RMH, Frieling JTM, van Tits HWHJ, et al: Endotoxemia after major vascular operations. J Vasc Surg 1993;18:853-857.
36. Jeukendrup AE, Vet-Joop K, Sturk A, et al: Relationship between gastro-intestinal complaints and endotoxaemia, cytokine release and the acute-phase reaction during and after a long-distance triathlon in highly trained men. Clin Sci (Lond) 2000;98:47-55.
37. Wiedermann CJ, Kiechl S, Dunzendorfer S, et al: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J Am Coll Cardiol 1999;34: 1975-1981.
38. Erridge C, Attina T, Spickett CM, Webb DJ: A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007;86:1286-1292.
39. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307: 1225-1230.
40. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-436.
41. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, the CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5.
42. Cruz DN, Perazella MA, Bellomo R, et al: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
43. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301: 2445-2452.
44. Angus DC, Birmingham MC, Balk RA, et al: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000;283:1723-1730.
45. Dellinger RP, Tomayko JF, Angus DC, et al: Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009;37:2929-2938.
46. Netea MG, Van Der Graaf CA, Vonk AG, Verscheueren I, van der Meer JW, Kullberg BJ: The role of Toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185: 1483-1489.
47. Van Der Graaf CA, Netea MG, Morr̈ SA, et al: Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006;17:29-34.
48. Lowry SF: Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 2007;24(Suppl 1):94-100.
49. Taveira Da Silva AM, Kaulach HC, Chuidian FS, Lambert DR, Stuffredini AF, Danner RL: Brief report: shock and multiple organ dysfunction after self administration of salmonella endotoxin. N Engl J Med 1993; 328:1457-1460.